Products
Pre-made Ranibizumab benchmark antibody ( Fab, anti-VEGFA therapeutic antibody, Anti-VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-470
Pre-Made Ranibizumab biosimilar, Fab, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-470-1mg | 1mg | 3090 | ||
| GMP-Bios-ab-470-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-470-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-470-xmg | ＞100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Ranibizumab biosimilar, Fab, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody |
| INN Name | Ranibizumab |
| Target | VEGFA |
| Format | Fab |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 1cz8:HL:YX |
| 99% SI Structure | None |
| 95-98% SI Structure | 1bj1:HL:KJ/6bft:HL:AB |
| Year Proposed | 2004 |
| Year Recommended | 2004 |
| Companies | Genentech;Manhattan Eye Ear & Throat Hospital;Novartis Ophthalmics;University of Bonn |
| Conditions Approved | Choroidal neovascularisation;Degenerative myopia;Diabetic macular oedema;Retinal oedema;Wet age-related macular degeneration;Diabetic retinopathy |
| Conditions Active | Retinopathy of prematurity;Polypoidal choroidal vasculopathy |
| Conditions Discontinued | Retinal telangiectasis |
| Development Tech | na |
